Skip to main content
SLBTSL Science Holding LimitedSell4.2·$2.66-1.85%
SellModerate Confidence
Investment thesis

SL Science Holding shows weak fundamental quality (0/9 Piotroski, no moat) and a confirmed falling-knife downtrend (death cross, RSI 39, bearish MACD), and the engine's own asymmetry check models 0% upside even though a resistance-based price target implies 137% upside — a conflict the data does not resolve, keeping the stock flagged for exit.

Thesis pillars

  • Weak Quality No MoatStable
  • Confirmed Falling Knife DowntrendImproving
  • Upside Estimate ConflictStable
  • +1 more pillar — see the Why tab for full reasoning

Full reasoning →

Open full analysis

SL Science Holding Limited (SLBT) Stock Analysis

Recovery setup

SellVALUE-TRAP 2/5QualityShortModerate Confidence

Healthcare · Biotechnology

Sell if holding. Momentum 2.9/10 is below the 5.0 floor at $2.66 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Weak overall score: 4.2/10; Weak growth.

SL Science Holding Limited manufactures cosmetic skin care and scalp care products. The company's products include SL bio's milk-derived exosome essence, SL bio's tangerine-derived extract, and the MilkExo concentrate series. It also offers research services in armed T-cells,... Read more

$2.66+56.0% A.UpsideScore 4.2/10#231 of 240 Biotechnology
QualityF-score5 / 9FCF yield
Stop $2.47Target $4.15(resistance)A.R:R 0.0:1

Sell if holding. Momentum 2.9/10 is below the 5.0 floor at $2.66 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Weak overall score: 4.2/10; Weak growth. Chart setup: Death cross but MACD improving, RSI 47. Score 4.2/10, moderate confidence.

Passes 5/8 gates (clean insider activity, no SEC red flags, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: speculative.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated 2026-08-15

Thesis

Rewards
No bull case signals
Risks
Weak overall score: 4.2/10
Weak growth
Negative momentum

Key Metrics

P/E (TTM)
P/E (Fwd)
Mkt Cap$1.5B
EV/EBITDA-2.9
Profit Mgn-72.5%
ROE
Rev Growth-7.6%
Beta
DividendNone
Rating analysts

Quality Signals

Piotroski F5/9MoatNarrow

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

3 floor-breakers

Revenue shrinking — -7.6% YoY. Growth thesis broken unless recovery story develops.static

Revenue Growth
0.6
Declining revenue: -8%
Low model confidence on this dimension (33%).

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Volume
0.0
Obv
1.0
Ma Position
1.0
Rsi
4.5
Macd
8.0
Volume distribution (falling OBV)Below 200-MA, MA slope -11.0%/30d — confirmed downtrend

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Quality Rank
1.5
Growth Rank
3.4
Value Rank
5.0
GatesMomentum 2.9<4.5Death cross (50MA < 200MA)A.R:R UPSIDE_EXHAUSTED (upside=0.0%)Insider activity: OKNo SEC red flagsEARNINGS PROXIMITY NO DATESEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARRecoverySuitability: Speculative
RSI
47 · Neutral
20D MA 50D MA 200D MADEATH CROSSSupport $2.54Resistance $4.23

Price Targets

$2
$4
A.R:R0.0:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! momentum at 2.9 (below the engine's 4.5 threshold)
! Death cross — 50-day MA below 200-day MA

Earnings

We could not retrieve earnings history for SLBT.
The company may be recently listed, pre-revenue, or its beat/miss record wasn't available from our source this run. Earnings signals feed the Growth and Catalyst score dimensions — absence here doesn't affect other dimensions.

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is SLBT stock a buy right now?

Sell if holding. Momentum 2.9/10 is below the 5.0 floor at $2.66 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Weak overall score: 4.2/10; Weak growth. Chart setup: Death cross but MACD improving, RSI 47. Prior stop was $2.47. Score 4.2/10, moderate confidence.

What is the SLBT stock price target?

Take-profit target: $4.15 (+56.0% upside). Prior stop was $2.47. Stop-loss: $2.47.

What are the risks of investing in SLBT?

Weak overall score: 4.2/10; Weak growth; Negative momentum.

Is SLBT overvalued or undervalued?

SL Science Holding Limited trades at a P/E of N/A (forward N/A). TrendMatrix value score: 5.0/10. Verdict: Sell.

0
What does SL Science Holding Limited do?SL Science Holding Limited manufactures cosmetic skin care and scalp care products. The company's products include SL...

SL Science Holding Limited manufactures cosmetic skin care and scalp care products. The company's products include SL bio's milk-derived exosome essence, SL bio's tangerine-derived extract, and the MilkExo concentrate series. It also offers research services in armed T-cells, gamma delta T- cells, citrus reticulata (tangerine) extract, and milk-derived exosomes. SL Science Holding Limited was formerly known as SL BIO Co., Ltd. and changed its name to SL Science Holding Limited in June 2026. The company is based in Taipei, Taiwan.

Related stocks: CRMD (CorMedix Inc.) · HRMY (Harmony Biosciences Holdings, I) · ZVRA (Zevra Therapeutics, Inc.) · AUPH (Aurinia Pharmaceuticals Inc) · INVA (Innoviva, Inc.)
Home Stocks SLBT

Latest news

Latest News

Benzinga4d agoProduct
Benzinga12d ago
Benzinga16d ago
Benzinga29d agoProduct
Benzinga32d ago
Benzinga36d agoFda Decision
Benzinga40d ago
Benzinga41d ago
Benzinga44d ago
Benzinga44d ago
Benzinga45d ago